| |
|
 |
 |
 |
|
|
|
 |
|
|
|
 |
|
|
AMT confirms efficacy of its LPL gene
therapy
|
|
Amsterdam Molecular
Therapeutics B.V. (AMT), announced that it has confirmed
the efficacy of its lipoprotein lipase (LPL) gene
therapy in a second animal model. The results, presented
at the European Society of Gene Therapy meeting in
Edinburgh, confirmed that intramuscular injection of
AMT`s LPL gene therapy product in a natural inherited
feline model of LPL deficiency induced a greater than
90% reduction of plasma triglyceride levels. AMT`s gene
therapy product for the potential treatment of LPL
deficiency in humans is an AAV vector expressing the
human LPL gene. The triglyceride levels started to
decline as early as one week following administration.
Triglyceride levels returned to pretreatment levels
after 2-4 weeks as a result of the predicted immune
response against the human LPL expressed in these
animals. It is anticipated that this immune response
will be absent in the future treatment of patients. An
earlier proof of principle study in mice had also shown
positive safety and efficacy. "These results support the
company`s decision to accelerate the development of the
product and the manufacturing program to support
clinical development and further commercialisation is
now well underway", Dr. Jan Boesen, CEO of AMT says.
These new data are the result of AMT sponsored
collaboration between Professor Michael Hayden at the
University of British Columbia, Vancouver, Canada and
Professor John Kastelein at the Academic Medical Center
(AMC) in Amsterdam. AMT licensed the LPL gene therapy
technology exclusively from Xenon Genetics Inc,
Vancouver, Canada and the AAV technology from the German
Cancer Institute at Heidelberg,
Germany.
|
(Source: Amsterdam Molecular
Therapeutics, 26-11-2003)
|
^top^ |
|
Scientific advisor Karl Stetter honored
with Leeuwenhoek medal
|
|
(Source: PR newswire,
25-11-2003) (Diversa website)
|
^top^ |
|
SEQUENOM obtains technology patent in
Europe
|
|
(Source: PRNewswire,
11-12-2003)
|
^top^ |
|
Revolutionary weapon for the war on
cancer
|
At
the American Society of Hematology meeting in San Diego,
CA, Cancer Genetics, Inc. (CGI) launched a new, highly
sensitive DNA FISH assay to help diagnose and monitor
therapy of chronic myeloid leukemia (CML) and a subset
of acute lymphoblastic leukemia (ALL). This assay is the
first "repeat-free" BCR/ABL four color fluorescent in
situ hybridisation (F-FISH) probe and it is CGI`s first
product to be introduced into the United States. This
F-FISH platform is used to simultaneously detect the
t(9;22)(q34.1;q11.2) translocations, associated
deletions, variants, and amplifications which occur in
CML. The assay design improves sensitivity and
specificity, eliminating false positive and false
negative results in patient samples. The design of
earlier generation probes limited sensitivity and
specificity and may not detect deletions and atypical
signal patterns arising from complex rearrangements. The
F-FISH probe was developed by using CGI`s proprietary
Signal Exchange Approach methodology, wherein probes are
derived from the regions flanking genes which contain
the breakpoints. The Company has filed patent
applications covering its proprietary signal segregation
approach, signal exchange approach, and repeat removal
technology. Cancer Genetics, Inc. probes are labeled
with the patented Universal Linkage System (ULS) from
KREATECH Biotechnology BV, Amsterdam, The Netherlands.
|
(Source: Business Wire,
05-12-2003) (Cancer Genetics website)
|
^top^ |
|
Trial of new investigational AIDS vaccine
starts
|
The Aaron Diamond AIDS
Research Center (ADARC), an affiliate of The Rockefeller
University, and the International AIDS Vaccine
Initiative (IAVI) announced that they have begun a human
trial of a new investigational vaccine to prevent
HIV/AIDS. The trial is actively seeking healthy
volunteers in New York City and Rochester, New York. The
trial is designed to evaluate the safety of a new DNA
vaccine called ADVAX. The vaccine is designed to
stimulate immune responses to prevent people who are
uninfected with HIV/AIDS from contracting the disease,
and the trial will gather preliminary data on whether
ADVAX stimulates these immune responses. The ADVAX
vaccine uses synthetic DNA based on a part of the
genetic material found in HIV. Unlike traditional
vaccines that contain a weakened or killed form of a
disease-causing agent, DNA vaccines instead contain only
portions of the genetic material. This means ADVAX
cannot cause HIV infection or AIDS. The International
AIDS Vaccine Initiative) is a global nonprofit
scientific organisation working to speed the search for
a vaccine to prevent HIV/AIDS. IAVI sponsors research
partnerships to develop and test promising vaccine
candidates. IAVI`s major financial supporters include
among others the Bill & Melinda Gates Foundation;
the Rockefeller; the World Bank; the UK Department for
International Development, the US Agency for
International Development, the Netherlands Ministry of
Foreign Affairs, Development Cooperation Ireland, the
Ministry of Foreign Affairs of Denmark, the Norwegian
Royal Ministry of Foreign Affairs and the Swedish
International Development Cooperation
Agency.
|
(IAVI website)
|
^top^ |
|
| |
|